NCT03341871 is a clinical trial in Hepatitis C Virus (HCV), sponsored by AbbVie.

Who is sponsoring NCT03341871?

NCT03341871 is sponsored by AbbVie.

What condition does NCT03341871 study?

NCT03341871 studies Hepatitis C Virus (HCV).

Is NCT03341871 still recruiting?

NCT03341871 is currently completed. Last updated 20 September 2021.

Last reviewed 2021-09-20 · How we verify

NCT03341871

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Glecaprevir/Pibrentasvir Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotype 1-6

Completed Last updated 20 September 2021

What this trial tests

trial in Hepatitis C Virus (HCV) in 1,095 participants. Completed in 15 September 2020.

Timeline

27 December 2017

Primary endpoint
15 September 2020

15 September 2020

Quick facts

Lead sponsor	AbbVie
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,095
Start date	27 December 2017
Primary completion	15 September 2020
Estimated completion	15 September 2020
Sites	1 location across Japan

Conditions studied

Hepatitis C Virus (HCV) — all drugs for Hepatitis C Virus (HCV) →

Sponsor

AbbVie — full company profile →

Who can join

Adults 0 to 99, any sex, with Hepatitis C Virus (HCV). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This multi-center, post-marketing, observational study evaluates the real world safety and effectiveness of glecaprevir plus pibrentasvir use in participants infected with the hepatitis C virus genotype 1 - 6.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Hepatitis C Virus (HCV)

Currently open trials in the same condition.

NCT07433985 — California MEPS Hub · NA · recruiting
NCT07122219 — Enhancing Uptake of Needle and Syringe Programs in Canadian Federal Prisons · NA · recruiting

Other AbbVie trials

Trials by the same sponsor.

NCT07219017 — A Study to Assess the Mass Balance of Oral ABBV-1354 in Healthy Adult Male Participants · Phase 1 · completed
NCT05316220 — A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years W · Phase 3 · withdrawn
NCT07024797 — Study to Assess the Adverse Events, Tolerability, and How Oral Doses of ABBV-932 Moves Through the Body in Healthy Adult · Phase 1 · completed
NCT07058051 — Cross-sectional Study to Characterize Real World Burden of Disease in Patients With Vitiligo in China · completed
NCT07007091 — A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administrations With a Pre-Filled · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03341871 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AbbVie
Last refreshed: 20 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03341871.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing